ArticleRSC advances2022
Platelet-rich fibrin (PRF) gel modified by a carbodiimide crosslinker for tissue regeneration.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- A scoping review on platelet-rich fibrin-driven bone regeneration: biological mechanisms and clinical applications in oral and maxillofacial surgery.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Platelet-derived biomaterials in osteoporosis: mechanisms, evidence and translational prospects.Journal of biological engineering · 2026Review
- Effect of bio-platelet rich fibrin as an adjuvant covering did not decrease the incidence of post-operative complications after urethroplasty in proximal hypospadias.International urology and nephrology · 2026Article
- Fibrin Gel as a Versatile Biomaterial Platform in the Biomedical Landscape: Chemical, Physical, and Biological Insights.Gels (Basel, Switzerland) · 2026Article
- A Semisolid Polymer-Based Electrochemical Cell for Electrostimulated Lactate Detection.ACS omega · 2025Article
- Tannic acid modified horizontal platelet-rich fibrin membrane with improved mechanical and biological properties for tissue regeneration : Author full names.Scientific reports · 2025Article
- The evolution of three generations of platelet concentrates products: a leap from classical formulations to the era of extracellular vesicles.Frontiers in bioengineering and biotechnology · 2025Review
- Improving properties of platelet-rich fibrin scaffold with tannic acid for wound healing.International wound journal · 2024Article
- Comparison of the effect of albumin with platelet-rich fibrin (Alb-PRF) gel and hyaluronic acid gel injection on interdental papilla reconstruction: A randomized clinical trial.Journal of advanced periodontology & implant dentistry · 2024Article
- Article
- The Potential Therapeutic Effects of Platelet-Derived Biomaterials on Osteoporosis: A Comprehensive Review of Current Evidence.International journal of biomaterials · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich fibrin (PRF) as a rich source of effective growth factors has been used as a scaffold in tissue regeneration. It is known that PRF exhibits rapid degradability against enzymes, which should be decreased using crosslinking agents to reduce the release rate of growth factors and increase the effectiveness of tissue regeneration. In this study, a carbodiimide crosslinker with different concentrations (0.01%, 0.05%, 1%, and 2%) was used to modify and improve the properties of PRF gel. The crosslinked gels were evaluated with analyses such as SEM, swelling, degradability, mechanical strength, release test, cytotoxicity, and cell adhesion. The results showed that with increasing crosslinker concentration, the morphology of the fiber structure changes drastically, the swelling rate decreases from 300% (control) to 160% for the crosslinked gel, the degradation time for the control sample increases from 8 days to more than two weeks for the crosslinked gel, and the Young's modulus increases from 0.15 MPa (control) to 0.61 MPa for the crosslinked samples. Growth factors also showed lower release with increasing crosslinking ratio. Cytotoxicity assays demonstrated that by increasing the crosslinker concentration to 1% w/v, no cytotoxicity was observed. Cellular studies with DAPI staining showed that the cells penetrated well into the gels and were well distributed, especially in gels with lower crosslinker concentrations. In addition, the modified PRF gel can be used as a scaffold for tissue regeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.